FindTrial
Sign In

Multi-Omics profiling of long noncoding RNAs in clear cell renal cell carcinoma for characterization and clinical applications

Clinical translation of Multi-Omics sequencing in the personalized treatment of refractory renal cell carcinoma

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2500108546
Enrollment
Unknown
Registered
2025-09-01
Start date
2025-09-01
Completion date
Unknown
Last updated
2025-09-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Renal cell carcinoma

Interventions

Observational group:Patients with clear cell renal cell carcinoma (ccRCC) who underwent radical nephrectomy

Sponsors

Department of Urology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1.Pathologically confirmed renal cell carcinoma (RCC) specimens reviewed and diagnosed by two independent pathologists; 2.Patients who have undergone radical nephrectomy at Tongji Hospital after completing physical examination, imaging studies, and preoperative assessment; 3.Provision of written informed consent by the patient; 4.Age between 18 and 80 years, regardless of sex.

Exclusion criteria

Exclusion criteria: 1.Concurrent diagnosis of other primary organ malignancies at the time of RCC diagnosis; 2.Pathological samples diagnosed as non-renal cell carcinoma by two different pathologists.

Design outcomes

Primary

MeasureTime frame
Progression-Free survival;Overall survival;—

Countries

China

Contacts

Public ContactChen Ke

Department of Urology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.

shenke@hust.edu.cn+86 139 0719 4550

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026